Congenica has raised an additional £13.25 million, totalling £23.3 million overall for its series B funding round.
The investment round, led by Parkwalk Advisors, attracted new strategic investors including Digital China Health Technologies alongside follow-on funding from the existing investors.
The company was recently awarded a multi-year contract to be the exclusive provider of Diagnostic Decision Support Services for the world leading NHS Genomic Medicine Service, allowing clinicians to use its Sapientia platform and expert support services to interrogate the human genome to identify disease-causing variants.
It is now also looking to accelerate growth, with commercial scale-up to support further penetration into international markets, to expand on the initial focus of the US and China.
Dr David Atkins, chief executive of Congenica, said: “With the formalisation of our partnership with the NHS, we are now focused on accelerating the introduction of important new features to our platform. These funds will allow us to automate Sapientia, to support wider usage and reduce costs to healthcare providers, helping more clinicians provide accurate, rapid and cost-effective diagnoses to patients and their families.
“In addition, we can now begin to penetrate international markets. The deepening of our relationship with DCHealth gives us greater insight into the needs of the China market, with the recent development of an on-premise version of our platform the most notable example.”
The funding will drive the development of an enhanced product platform that harnesses the power of statistics and machine learning technology to augment the ability of users to make diagnostic decisions.